Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994746 | 1.00 | CHRM1 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL4001193 | 0.89 | ACE2 (0.55) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3995094 | 0.89 | ACE2 (0.55) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL21245498 | 0.87 | ACE2 (0.62) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3993703 | 0.86 | CHRM1 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL622838 | 0.86 | CHRM1 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL21245488 | 0.85 | ACE2 (0.66) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL21245504 | 0.85 | ACE2 (0.66) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL25406782 | 0.85 | — | — | |
| SCHEMBL6841354 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | UNIVERSITY OF OTAGO (NZ) | 2020-10-15 | — | — | US | claimed |
| CN-111630026-A | Sustained release pharmaceutical formulations and methods of treatment | 道格拉斯制药有限公司 | 2020-09-04 | — | — | CN | claimed |
| EP-3694832-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | Douglas Pharmaceuticals Limited (NZ) | 2020-08-19 | — | — | EP | claimed |
| US-10744094-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2020-08-18 | — | — | US | claimed |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-07-25 | — | — | US | claimed |
| WO-2019073408-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | DOUGLAS PHARMACEUTICALS LTD. (NZ) | 2019-04-18 | — | — | WO | claimed |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2019-04-11 | — | — | US | claimed |
| EP-1614675-A2 | Amino acids with affinity for the alpha-2-delta protein | Warner-Lambert Company LLC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | BARTA NANCY SUE | 2005-12-08 | — | — | US | claimed |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20240189259-A2 | Extended Release Pharmaceutical Formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2024-06-13 | — | — | US | disclosed |
| EP-4377309-A1 | CRYSTALLINE FORMS | RaQualia Pharma Inc. (JP) | 2024-06-05 | — | — | EP | disclosed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | disclosed |
| US-20230355548-A1 | Extended Release Pharmaceutical Formulation | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2023-11-09 | — | — | US | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005030184-A2 | THERAPEUTIC BETA AMINOACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1492761-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY SUE (US) | 2003-10-16 | — | — | US | disclosed |
| WO-2003082807-A2 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323795-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | CRH, HTR5A, NPY5R | CHRM1 3059/4885AKR1A1 1406/4885CHRM3 1751/4885 |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CHRM1 2872/4885AKR1A1 4215/4885CHRM3 2717/4885 |
| US-20230355548-A1 | Extended Release Pharmaceutical Formulation | CRH, HTR6, HTR5A | CHRM1 2988/4885AKR1A1 1947/4885CHRM3 2208/4885 |
| US-20030195251-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, CAMK2A | CHRM1 2860/4885AKR1A1 4393/4885CHRM3 2651/4885 |
| US-20240189259-A2 | Extended Release Pharmaceutical Formulation | CRH, HTR6, HTR5A | CHRM1 2988/4885AKR1A1 1947/4885CHRM3 2208/4885 |
| US-20050272783-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CHRM1 2808/4885AKR1A1 4148/4885CHRM3 3193/4885 |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | CHRM1 2903/4885AKR1A1 137/4885CHRM3 2714/4885 |
| US-20190224127-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | CRH, HTR5A, HTR6 | CHRM1 3134/4885AKR1A1 753/4885CHRM3 1890/4885 |
| US-10744094-B2 | Extended release pharmaceutical formulation | CRH, HTR5A, HTR6 | CHRM1 3134/4885AKR1A1 753/4885CHRM3 1890/4885 |
| US-20190105276-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | CRH, HTR5A, HTR6 | CHRM1 3134/4885AKR1A1 753/4885CHRM3 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.